EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.

Authors :: Giustini NP
Pritchard CC
Kamat NV
Menon MP
Source :: JCO precision oncology [JCO Precis Oncol] 2024 Jul; Vol. 8, pp. e2300215.
Publication Year :: 2024
Abstract: Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.

Subjects :: Humans
Male
Antineoplastic Agents therapeutic use
Female
Middle Aged
Mutation
Aged
Indoles
Pyrimidines
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung genetics
Aniline Compounds therapeutic use
Acrylamides therapeutic use
Lung Neoplasms drug therapy
Lung Neoplasms genetics
ErbB Receptors genetics

Full Text Access

Tools